UTime Limited has signed a non-disclosure agreement to acquire Bowen Therapeutics Inc, a company focused on the R&D of vaccines for infectious diseases, particularly monkeypox. The acquisition will allow UTime to enhance its presence in the global vaccine market and support the FDA registration of Bowen’s hexavalent recombinant protein vaccine. This strategic move reflects growing concerns over monkeypox, an infectious disease that has alarmed the global community. UTime will take over the Bowen Therapeutics laboratory at UMASS Medical School and will handle ongoing clinical trials and future vaccine development programs. The deal is subject to regulatory approvals and customary conditions and is expected to be completed within a few months, indicating UTime’s commitment to addressing global public health challenges efficiently.
Healthcare, Pharmaceutical, Technology,China, United States, Global
https://contentapi.cision.com/api/v1.0/releases/20240828EN93409